Profusa, Inc. (NASDAQ:PFSA) Short Interest Update

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 234,995 shares, an increase of 90.3% from the June 15th total of 123,461 shares. Based on an average daily volume of 13,939,399 shares, the short-interest ratio is presently 0.0 days. Currently, 127.0% of the company’s stock are sold short.

Profusa Trading Down 7.0%

Shares of Profusa stock opened at $1.73 on Friday. The firm’s 50 day simple moving average is $6.05 and its two-hundred day simple moving average is $50.67. The firm has a market capitalization of $328,700.00, a price-to-earnings ratio of -0.00 and a beta of 0.46. Profusa has a 12-month low of $1.69 and a 12-month high of $4,162.50.

Profusa (NASDAQ:PFSA) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $2,231.25 EPS for the quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFSA. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.